Fluorouracil-based chemotherapy combined with anti–epidermal growth factor receptor/vascular endothelial growth factor therapy is the standard first-line treatment for metastatic colorectal cancer followed by low-intensity maintenance therapy to balance the clinical efficacy and adverse effects (AEs). This evidence concerns the gene EGFR and metastatic colorectal cancer.